Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 4/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2864897 | 1.00 | PDE4B (0.39) | PDE4BMAPTALDH1A1GFERGRIN2B | |
| SCHEMBL4235124 | 0.94 | NOTUM (0.37) | PDE4BMAPTALDH1A1GRIN2BHPGD | |
| SCHEMBL4235120 | 0.94 | NOTUM (0.37) | PDE4BMAPTALDH1A1GRIN2BHPGD | |
| SCHEMBL4234636 | 0.92 | TP53 (0.34) | MAPTALDH1A1GRIN2BHPGDACACB | |
| SCHEMBL4234632 | 0.92 | TP53 (0.34) | MAPTALDH1A1GRIN2BHPGDACACB | |
| SCHEMBL4236051 | 0.89 | DPP7 (0.40) | GRIN2BHPGDTP53DPP4DPP7 | |
| SCHEMBL4236056 | 0.89 | DPP7 (0.40) | GRIN2BHPGDTP53DPP4DPP7 | |
| SCHEMBL2867031 | 0.86 | DPP4 (0.38) | MAPTDPP4DPP7DPP8DPP9 | |
| SCHEMBL2867029 | 0.86 | DPP4 (0.38) | MAPTDPP4DPP7DPP8DPP9 | |
| SCHEMBL2869459 | 0.85 | CYP17A1 (0.35) | PDE4BGRIN2BHPGDLPAR5DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | claimed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | claimed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | claimed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | claimed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | claimed |
| EP-2245020-B1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8383657-B2 | Thiazolylidine urea and amide derivatives and methods of use thereof | ABBOTT LABORATORIES (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2245020-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2010-11-03 | — | — | EP | disclosed |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-09-03 | — | — | US | disclosed |
| WO-2009086163-A2 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | WO | disclosed |
| WO-2009082698-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | ABBOTT LABORATORIES (US) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163470-A1 | THIAZOLYLIDINE UREA AND AMIDE DERIVATIVES AND METHODS OF USE THEREOF | NMUR1, NMUR2, PAM | PDE4B 324/4885MAPT 465/4885ALDH1A1 2649/4885 |
| US-20090221648-A1 | COMPOSITIONS FOR TREATMENT OF COGNITIVE DISORDERS | CHRNA4, CHRNA5, CHRNA3 | PDE4B 235/4885MAPT 290/4885ALDH1A1 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.